Everything you need to know about Actelion, a Johnson & Johnson company treating pulmonary arterial hypertension (PAH).
It’s one hard-working organ, pumping 1.5 gallons of blood every minute and beating around 100,000 times a day. In honor of Pulmonary Hypertension Awareness Month, we sat down with a ticker expert to learn about things most people may not know about their hearts—and advances that could change cardiac care.
133 years of innovative Credo-driven decisions that have made Johnson & Johnson the healthcare leader it is today
To help mark 75 years since the company went public, we’re retracing some of the pivotal acquisitions, inventions and decisions that have guided the company for more than a century.
In this recap of Johnson & Johnson’s latest earnings report, you can learn how the company’s consumer, pharmaceutical and medical devices businesses performed in the second quarter of 2018.
Learn how the company’s consumer, pharmaceutical and medical devices businesses performed in the first quarter of 2018 in this recap of Johnson & Johnson’s latest earnings report.
See how the company’s consumer, pharmaceutical and medical devices businesses performed in 2017 in this breakdown of its latest annual earnings report.
It’s a deadly disease, but it can be managed—if you get a timely diagnosis. For World Heart Day, we’re sharing what the latest science and research has revealed about PAH, including who is most at risk and the warning signs to look out for.
Joaquin Duato, Executive Vice President and Worldwide Chairman, Pharmaceuticals, shares how the transaction will help expand the company’s portfolio of transformational therapies.